Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Bayer
Boehringer Ingelheim
Seagen Inc.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
OncoC4, Inc.
USWM, LLC (dba US WorldMeds)
Pfizer
Iovance Biotherapeutics, Inc.
Modulation Therapeutics, Inc.
Pfizer
Bayer
iOnctura
Genentech, Inc.
Dana-Farber Cancer Institute
University of Southern California
National Cancer Institute (NCI)
Mayo Clinic
The Methodist Hospital Research Institute
TILT Biotherapeutics Ltd.
H. Lee Moffitt Cancer Center and Research Institute
Replimune, Inc.
University Hospital, Basel, Switzerland
Erasca, Inc.
Ohio State University Comprehensive Cancer Center
Phio Pharmaceuticals Inc.
Werewolf Therapeutics, Inc.
Jonsson Comprehensive Cancer Center
Sandoz
ModernaTX, Inc.
City of Hope Medical Center
Novartis
Mayo Clinic
AbbVie
AgonOx, Inc.
University of Southern California
UNC Lineberger Comprehensive Cancer Center
Novartis
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Pierre Fabre Medicament